secwatch.observer — SEC 8-K summary
======================================

Issuer:     Amneal Pharmaceuticals, Inc. (AMRX)
CIK:        0001723128
Form:       8-K
Filed at:   2023-10-17T23:59:59+00:00
Accession:  0001193125-23-257254
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Amneal to eliminate Up-C structure, form NewCo; expects $30M annual tax-distribution savings
--------------------------------------------------------------------------------

- Binding term sheet executed Oct. 16, 2023 to reorganize into single-class structure via new Delaware holding company (NewCo).
- All existing Class A and Class B shares convert to NewCo Class A common stock; target completion November 2023.
- Six-month 2023 tax-related cash distributions were $30M; elimination expected to improve cash flows and reduce debt.
- Tax Receivable Agreement amended: Amneal Legacy Group's share of tax savings reduced from 85% to 75%; no cash consideration.
- NewCo to trade under same ticker AMRX on NYSE; management and board unchanged.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523257254/0001193125-23-257254-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1723128/000119312523257254/d560382d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-257254

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer